Junhang Luo
Overview
Explore the profile of Junhang Luo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
916
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang Y, Yang T, Li Q, Zheng Z, Liao L, Cen J, et al.
Mol Cancer
. 2025 Jan;
24(1):1.
PMID: 39748364
Background: Clear cell renal cell carcinoma (ccRCC) represents the most prevalent subtype, accounting for nearly 80% of all RCC cases. Recent research has shown that high expression of circular non-coding...
2.
Yu A, Fu L, Jing L, Wang Y, Ma Z, Zhou X, et al.
Cell Death Differ
. 2024 Dec;
PMID: 39672819
The impact of amino acids on tumor immunotherapy is gradually being uncovered. In this study, we screened various essential and non-essential amino acids and found that methionine enhances mRNA methylation...
3.
Luo J, Lin M, Chen M, Chen J, Zhou X, Liu K, et al.
Transl Oncol
. 2024 Nov;
51:102180.
PMID: 39536695
Background: Natural killer cells, interconnected with patient prognosis and treatment response, play a pivotal role in the tumor immune microenvironment and may serve as potential novel predictive biomarkers for renal...
4.
Huang G, Liu J, Yu A, Luo C, Zhu J, Wang Y, et al.
Cell Mol Life Sci
. 2024 Jul;
81(1):292.
PMID: 38976080
Cisplatin resistance is a major challenge for systemic therapy against advanced bladder cancer (BC). Little information is available on the regulation of cisplatin resistance and the underlying mechanisms require elucidation....
5.
Li P, Tang Y, Zeng Q, Mo C, Ali N, Bai B, et al.
Heliyon
. 2024 May;
10(10):e30956.
PMID: 38818205
Objective: This study aims to investigate the predictive performance of machine learning in predicting the occurrence of systemic inflammatory response syndrome (SIRS) and urosepsis after percutaneous nephrolithotomy (PCNL). Methods: A...
6.
Li P, Xu Q, Chen M, Zhu J, Wang Y, Mumin M, et al.
Cancer Med
. 2024 Mar;
13(5):e6813.
PMID: 38477529
Background: TFE3 immunohistochemistry (TFE3-IHC) is controversial in the diagnosis of TFE3-rearranged renal cell carcinoma (TFE3-rearranged RCC). This study is to investigate the accuracy and sensitivity of IHC and establish a...
7.
Lin H, Fu L, Zhou X, Yu A, Chen Y, Liao W, et al.
Cancer Lett
. 2024 Mar;
593:216807.
PMID: 38462037
The tumour microenvironment (TME) drives bladder cancer (BLCA) progression. Targeting the TME has emerged as a promising strategy for BLCA treatment in recent years. Furthermore, checkpoint blockade therapies are only...
8.
PABPC1L Induces IDO1 to Promote Tryptophan Metabolism and Immune Suppression in Renal Cell Carcinoma
Shu G, Chen M, Liao W, Fu L, Lin M, Gui C, et al.
Cancer Res
. 2024 Feb;
84(10):1659-1679.
PMID: 38382068
Significance: PABPC1L functions as a key factor in renal cell carcinoma immune evasion, enhancing IDO1 and impeding T-cell function, and represents a potential target to enhance the efficacy of immune...
9.
Wei L, Li Z, Guo S, Ma H, Shi Y, An X, et al.
Cancer
. 2023 Dec;
130(9):1650-1662.
PMID: 38157276
Background: Penile squamous cell carcinoma (PSCC) is a human papillomavirus (HPV)-associated malignancy. Immunotherapy is emerging as a potential treatment for advanced PSCC. In this study, the authors analyzed the association...
10.
Zhang J, Yao H, Lai C, Sun X, Yang X, Li S, et al.
Chin J Cancer Res
. 2023 Nov;
35(5):511-525.
PMID: 37969955
Objective: DNA methylation alterations are early events in carcinogenesis and immune signalling in lung cancer. This study aimed to develop a model based on short stature homeobox 2 gene ()/prostaglandin...